Close this search box.
Close this search box.

Metyos: Pioneering the Development of Biowearable Arm Patches to Monitor Chronic Kidney Disease

Image Credits: Metyos
By: Headliners News / April 2, 2024

Meet Metyos, an innovative HealthTech startup led by CEO Alexandre Boulanger and CTO Olga Chashchina, is pioneering the development of a biowearable arm patch designed to monitor chronic kidney disease (CKD). Inspired by the success of biowearables like continuous glucose monitors (CGMs) for diabetes management, Metyos aims to offer real-time sensing technology capable of detecting chemical changes in fluids just under the skin, specifically targeting biomarkers linked to CKD.

The startup’s mission is twofold: to empower patients by providing them with actionable insights and recommendations for managing their condition, and to enable healthcare professionals to remotely monitor disease progression and intervene when necessary. By leveraging biowearable technology, Metyos seeks to bridge the gap between patients and doctors, facilitating proactive and personalized care for CKD.

Metyos’ biowearable arm patch monitors ions and minerals indicative of kidney dysfunction, transmitting data to a smartphone app via Bluetooth. This data is then securely relayed to Metyos’ cloud server, where healthcare professionals can access it for remote monitoring and analysis. The startup’s approach promises to revolutionize CKD management by providing timely insights and facilitating early intervention to prevent adverse events.

Since its inception in 2021, Metyos has made significant progress, developing a prototype of its biowearable and conducting preliminary bench tests. With the recent closure of a pre-seed funding round totaling €2.3 million (~$2.5 million), led by investors including Cenitz, Bpifrance, and KIMA Ventures, the startup is poised to advance to the next stage of development. This phase will involve running clinical trials to further evaluate and refine the technology, with regulatory approval targeted by the end of 2025.

Boulanger and Chashchina’s vision for Metyos emerged from personal experiences with chronic health conditions, driving their passion for improving patient care through innovative biowearable solutions. By partnering with doctors and prioritizing user-centric design, Metyos aims to address the clinical needs of CKD patients while revolutionizing remote patient monitoring.

With over 800 million CKD patients worldwide, Metyos recognizes the urgency and significance of their mission. By focusing on end-stage patients with hyperkalemia issues initially and expanding to earlier stages over time, the startup aims to make a meaningful impact on the lives of CKD patients and the healthcare system as a whole.

Within a fairly competitive landscape, Metyos really stands out for its targeted approach to CKD monitoring, distinguishing itself from other biowearable startups by its singular focus on kidney conditions and real-time data collection. While competition in the space is growing, Metyos’ dedication to improving CKD management positions it as a leader in the burgeoning field of biowearable technology.

What do you think?

2 People voted this article. 2 Upvotes - 0 Downvotes.
Please Share This